Longitudinal assessment of liver fibrosis with transient elastometry (TE) in patients with chronic viral hepatitis is becoming routine clinical practice in many clinics, as this procedure is non-invasive, easy to perform and relatively inexpensive, allowing early detection of cirrhosis. Herein, we examine the incidence of cirrhosis, using TE assessment, in HIV-infected individuals with chronic hepatitis B or C receiving highly active anti-retroviral therapy (HAART).
Methods
A longitudinal study was performed on a cohort of HIV-infected patients with chronic hepatitis B or C who were followed since 2004 at Hospital Carlos III (Madrid, Spain) with periodic TE assessments. The primary outcome was the development of cirrhosis, defined as liver stiffness >12.5 KPa.
Results
A total of 508 HIV-infected patients were examined, of whom 54 developed liver cirrhosis during a mean ±sd follow-up of 2.6 ±1.0 years (overall incidence was 41.13 cases per 1,000 person-years). The risk of developing cirrhosis was significantly higher in 297 HCV-RNA-positive patients (either untreated or non- responders to hepatitis C therapy) compared with 55 patients who had cleared HCV with therapy (odds ratio 3.73, 95% confidence interval 1.06–13.17; P=0.04). By contrast, the risk of developing cirrhosis was low and similar in 24 HIV–HBV-coinfected patients under long-term suppressive HBV therapy (mainly tenofovir disoproxil fumarate), 132 HIV-infected patients without chronic liver disease and those who had cleared HCV with therapy.
Conclusions
Development of liver cirrhosis in HIV- infected individuals in the HAART era is mainly associated with active HCV coinfection. The risk of developing cirrhosis is negligible in patients who cleared HCV with therapy, as well as in HIV–HBV-coinfected patients on long-term suppressive tenofovir disoproxil fumarate therapy.
References
1.
The Data Collection on Adverse Events of Anti-HIV Drugs Study Group.Liver-related deaths in persons infected with the HIV: the D:A:D study.Arch Intern Med2006; 166: 1632–1641.
2.
SulkowskiM.S., MehtaS.H., TorbensonM.S.Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.AIDS2007; 21: 2209–2216.
3.
BrunoR., SacchiP., PuotiM.Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection.J Acquir Immune Defic Syndr2007; 46: 297–303.
4.
CastellaresC., BarreiroP., Martin-CarboneroL.Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome.J Viral Hepat2008; 15: 165–172.
5.
MaciasJ., BerenguerJ., JaponM.Fast fibrosis progression between repeated liver biopsies in patients coinfected with HIV/hepatitis C virus.Hepatology2009; 50: 1056–1063.
6.
ColinJ.F., Cazals-HatemD., LoriotM.A.Influence of HIV infection on chronic hepatitis B in homosexual men.Hepatology1999; 29: 1306–1310.
7.
TheinH.H., YiQ., DoreG.J., KrahnM.D.Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis.AIDS2008; 22: 1979–1991.
8.
de LédinghenV., BarreiroP., FoucherJ.Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy.J Viral Hepat2008; 15: 427–433.
9.
MaciasJ., CastellanoV., MerchanteN.Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.AIDS2004; 18: 767–774.
10.
SulkowskiM.S.Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.Clin Infect Dis2004; 38 Suppl 2: S90–S97.
11.
BlancoF., BarreiroP., RyanP.Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.J Viral Hepat2010. doi 10.1111/j.1365-2893.2009.01261.x.
12.
BalagopalA., PhilpF., AstemborskiJ.HIV-related microbial translocation and progression of hepatitis C.Gastroenterology2008; 135: 226–233.
13.
SulkowskiM.S., ThomasD.L., ChaissonR.E., MooreR.D.Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection.JAMA2000; 283: 74–80.
14.
MaidaI., Garcia-GascoP., SotgiuG.Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome.Antivir Ther2008; 13: 103–107.
15.
KovariH., LedergerberB., PeterU.Association of non-cirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.Clin Infect Dis2009; 49: 626–635.
16.
LanternierF., RoulotD., BentataM.Risks factors of liver fibrosis in a cohort of intravenous drug users coinfected with HIV and HCV in the HAART era: the role of mixed steatosis.Gastroenterol Clin Biol2007; 31: 822–827.
17.
QurishiN., KreuzbergC., LuchtersG.Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.Lancet2003; 362: 1708–1713.
18.
BrauN., SalvatoreM., Rios-BedoyaC.Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.J Hepatol2006; 44: 47–55.
19.
Pascual-ParejaJ.F., CaminoaA., LarrauriC.HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/[mu]l at the time of liver biopsy.AIDS2009; 23: 971–975.
20.
MaidaI., SorianoV., CastellaresC.Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity.HIV Clin Trials2006; 7: 246–250.
21.
MalletV.O., Dhalluin-VenierV., VerkarreV.Reversibility of cirrhosis in HIV/HBV coinfection.Antivir Ther2007; 12: 279–283.
22.
MiailhesP., TrabaudM., PradatP.Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.Clin Infect Dis2007; 45: 624–632.
23.
SorianoV., MaidaI., NúñezM.Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.Antivir Ther2004; 9: 987–992.
24.
BerenguerJ., Alvarez-PellicerJ., MartínP.Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus.Hepatology2009; 50: 407–413.
25.
BarreiroP., LabargaP., Martín-CarboneroL.Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients.Antivir Ther2006; 11: 869–877.
26.
Rodriguez-TorresM., Rodriguez-OrengoJ., Rios-BedoyaC.Effect of hepatitis C virus treatment in fibrosis progression rate and time to cirrhosis in patients co-infected with HIV: a paired liver biopsy study.J Hepatol2007; 46: 613–619.
27.
Bani-SadrF., LapidusN., BedossaP.Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.Clin Infect Dis2008; 46: 768–774.
28.
HalfonP., CarratF., BedossaP.Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.Antivir Ther2009; 14: 211–219.
29.
OgawaE., FurusyoN., ToyodaK., TakeokaH., MaedaS., HayashiJ.The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.Antiviral Res2009; 83: 127–134.
30.
SorianoV., Martín-CarboneroL., García-SamaniegoJ.Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis?AIDS2003; 17: 751–753.
31.
CasteraL., VergniolJ., FoucherJ.Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.Gastroenterology2005; 128: 343–350.
32.
de LédinghenV., DouvinC., KettanehA.Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients.J Acquir Immune Defic Syndr2006; 41: 175–179.
33.
KirkG.D., AstemborskiJ., MehtaS.H.Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection.Clin Infect Dis2009; 48: 963–972.
34.
SandrinL., FourquetB., HasquenophJ.M.Transient elastography: a new non-invasive method for assessment of hepatic fibrosis.Ultrasound Med Biol2003; 29: 1705–1713.
35.
DeeksS.G., PhillipsA.N.HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.BMJ2009; 338: a3172.
36.
IloejeU.H., YangH.I., SuJ., JenC.L., YouS.L., ChenC.J.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.Gastroenterology2006; 130: 678–686.
37.
Jiménez-NácherI., GarcíaB., BarreiroP.Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements.J Antimicrob Chemother2008; 62: 816–822.
38.
MarcellinP., HeathcoteE.J., ButiM.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.N Engl J Med2008; 359: 2442–2455.
39.
LeeT., NunezM.Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients.HIV Clin Trials2009; 10: 153–159.
40.
MehtaS.H., GenbergB.L., AstemborskiJ.Limited uptake of hepatitis C treatment among injection drug users.J Community Health2008; 33: 126–133.
41.
GrebelyJ., RaffaJ., LaiC.Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents.J Viral Hepat2009; 16: 352–358.
42.
TorrianiF.J., Rodriguez-TorresM., RockstrohJ.K.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.N Engl J Med2004; 351: 438–450.
43.
CarratF., Bani-SadrF., PolS.Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients.JAMA2004; 292: 2839–2848.
44.
NunezM., MirallesC., BerdunM.A.Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.AIDS Res Hum Retroviruses2007; 23: 972–982.
45.
SorianoV., PetersM., ZeuzemS.New therapies for hepatitis C virus infection.Clin Infect Dis2009; 48: 313–320.
46.
GeD., FellayJ., ThompsonA.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature2009; 461: 399–401.
47.
SuppiahV., MoldovanM., AhlenstielG.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.Nat Genet2009; 41: 1100–1104.
48.
TanakaY., NishidaN., SugiyamaM.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.Nat Genet2009; 41: 1105–1109.
49.
RallonN.I., NaggieS., BenitoJ.M.Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.AIDS2010; 24: F23–F29.
50.
SterlingR.K., ContosM.J., SmithP.G.Steatohepatitis: risk factors and impact on disease severity in HIV/hepatitis C virus coinfection.Hepatology2008; 47: 1118–1127.
51.
SchiaviniM., AngeliE., MaininiA.Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985–2002.HIV Med2006; 7: 331–337.
